 NLS Pharmaceutics Ltd NASDAQ: NLSP has announced interim topline data from its Phase 2a trial of its lead product candidate, Quilience Mazindol ER, in narcolepsy. For excessive daytime sleepiness EDS, the trials primary endpoint, patients on Mazindol ER exhibited a. 